Literature DB >> 32924430

Tetrahedral Framework Nucleic Acid Promotes the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaws by Promoting Angiogenesis and M2 Polarization.

Dan Zhao1, Weitong Cui1, Mengting Liu1, Jiajie Li1, Yue Sun1, Sirong Shi1, Shiyu Lin1, Yunfeng Lin1,2.   

Abstract

Bisphosphonates are often used to treat osteoporosis, malignant bone metastases, and hypercalcemia. However, it can cause serious adverse reactions, bisphosphonate-related osteonecrosis of the jaw (BRONJ), which seriously affects the quality of life of patients. At present, the treatment of BRONJ is still difficult to reach an agreement, and there is no effective treatment. Therefore, it is very important to find effective treatments. Many studies have shown that the occurrence of BRONJ may be due to unbalanced bone turnover, anti-angiogenesis, bacterial infection, direct tissue toxicity, and abnormal immune function. The previous research results show that tetrahedral framework nucleic acids (tFNAs), a new type of nanomaterial, can promote various biological activities of cells, such as cell proliferation, migration, anti-inflammation and anti-oxidation, and angiogenesis. Therefore, we intend to explore the potential of tFNAs in the treatment of BRONJ through this study. The results show that tFNAs can promote the treatment of BRONJ by promoting angiogenesis and promoting M2 polarization in macrophages and inhibiting M1 polarization both in vitro and in vivo. These results provide a theoretical basis for the application of tFNAs in the treatment of BRONJ and also provide new ideas and methods for the treatment of other diseases based on ischemia and immune disorders.

Entities:  

Keywords:  M1/M2 polarization; angiogenesis; bisphosphonate-related osteonecrosis of the jaws; endothelia cells; macrophages; tetrahedral framework nucleic acid

Year:  2020        PMID: 32924430     DOI: 10.1021/acsami.0c13839

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  10 in total

1.  Research progress on the application of framework nucleic acid in bone regeneration.

Authors:  Yun Feng Lin
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-12-01

Review 2.  Biological aspects in controlling angiogenesis: current progress.

Authors:  Mohsen Akbarian; Luiz E Bertassoni; Lobat Tayebi
Journal:  Cell Mol Life Sci       Date:  2022-06-07       Impact factor: 9.207

Review 3.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

Review 4.  The biological applications of DNA nanomaterials: current challenges and future directions.

Authors:  Wenjuan Ma; Yuxi Zhan; Yuxin Zhang; Chenchen Mao; Xueping Xie; Yunfeng Lin
Journal:  Signal Transduct Target Ther       Date:  2021-10-08

Review 5.  Applications of tetrahedral DNA nanostructures in wound repair and tissue regeneration.

Authors:  Yikai Dou; Weitong Cui; Xiao Yang; Yunfeng Lin; Xiaohong Ma; Xiaoxiao Cai
Journal:  Burns Trauma       Date:  2022-03-10

6.  Tetrahedral framework nucleic acid carrying angiogenic peptide prevents bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis.

Authors:  Dan Zhao; Dexuan Xiao; Mengting Liu; Jiajie Li; Shuanglin Peng; Qing He; Yue Sun; Jingang Xiao; Yunfeng Lin
Journal:  Int J Oral Sci       Date:  2022-04-27       Impact factor: 24.897

Review 7.  Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Ran Yan; Ruixue Jiang; Longwei Hu; Yuwei Deng; Jin Wen; Xinquan Jiang
Journal:  Int J Oral Sci       Date:  2022-08-10       Impact factor: 24.897

8.  Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ.

Authors:  Xin Shen; Weiwen Zhu; Ping Zhang; Yu Fu; Jie Cheng; Laikui Liu; Rongyao Xu; Hongbing Jiang
Journal:  JCI Insight       Date:  2022-08-22

Review 9.  Gene therapy to enhance angiogenesis in chronic wounds.

Authors:  Elnaz Shaabani; Maryam Sharifiaghdam; Reza Faridi-Majidi; Stefaan C De Smedt; Kevin Braeckmans; Juan C Fraire
Journal:  Mol Ther Nucleic Acids       Date:  2022-08-17       Impact factor: 10.183

10.  Myeloid cell-specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation.

Authors:  Yang Wang; Heela Sarlus; Keyi Geng; Keying Zhu; Erik Nutma; Jingxian Sun; Shin-Yu Kung; Cindy Bay; Jinming Han; Jin-Hong Min; Irene Benito-Cuesta; Harald Lund; Sandra Amor; Jun Wang; Xing-Mei Zhang; Claudia Kutter; André Ortlieb Guerreiro-Cacais; Björn Högberg; Robert A Harris
Journal:  EMBO Rep       Date:  2022-05-20       Impact factor: 9.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.